DNA methylating, chemotherapeutic agent. Displays antitumor activity against a board spectrum of tumors, including leukemias, lymphomas and solid tumors (IC50 = 5.0 μM for cytotoxicity against mouse TLX5 lymphoma cells). Induces autophagy in malignant glioma cells. Exhibits enhanced activity when used in combination with CHC (Cat No. 5029).
Temozolomide is also offered as part of the Tocriscreen Plus, Tocriscreen Epigenetics Toolbox and Tocriscreen Library of FDA-Approved Compounds. Find out more about compound libraries available from Tocris.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 194.15. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||5.15 mL||25.75 mL||51.51 mL|
|5 mM||1.03 mL||5.15 mL||10.3 mL|
|10 mM||0.52 mL||2.58 mL||5.15 mL|
|50 mM||0.1 mL||0.52 mL||1.03 mL|
References are publications that support the products' biological activity.
Plowman et al (1994) Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res. 54 3793 PMID: 8033099
Clark et al (1995) Antitumor imidazotetraazines. 32. Synthesis of novel imidazotetrazinones and related bicyclic heterocycles to probe the mode of action of the antitumor drug temozolomide. J.Med.Chem. 38 1493 PMID: 7739008
Bodell et al (2003) Formation of DNA adducts and induction of lacI mutations in big blue rat-2 cells treated with temozolomide: implications for the treatment of low-grade adult and pediatric tumors. Cancer Epidemiol.Biomarkers Prevent. 12 545 PMID:
Kanzawa et al (2004) Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ. 11 448 PMID: 14713959
If you know of a relevant reference for Temozolomide, please let us know.
Keywords: Temozolomide, supplier, DNA-methylating, antitumor, agent, Apoptosis, Inducer, NSC362856, CCRG81045, chemotherapeutics, NSC, 362856, CCRG, 81045, Apoptosis, Inducers, Autophagy, Apoptosis, Inducers, Tocris Bioscience
2 Citations for Temozolomide
Citations are publications that use Tocris products. Selected citations for Temozolomide include:
Pastori et al (2014) BET bromodomain proteins are required for glioblastoma cell proliferation. Epigenetics 9 611 PMID: 24496381
Hu et al (2012) Fibulin-3 promotes glioma growth and resistance through a novel paracrine regulation of Notch signaling. Cancer Res 72 3873 PMID: 22665268
Do you know of a great paper that uses Temozolomide from Tocris? If so please let us know.
Reviews for Temozolomide
There are currently no reviews for this product. Be the first to review Temozolomide and earn rewards!
Have you used Temozolomide?
Submit a review and receive an Amazon gift card.
$10US/$10CAN/€7/£6 gift card for a review without an image
$25US/$25CAN/€18/£15 gift card for a review with an image
*Offer only valid in the USA / Canada, UK and EuropeSubmit a Review
Literature in this Area
Programmed Cell Death Poster
There are two currently recognized forms of programmed cell death: apoptosis and necroptosis. This poster summarizes the signaling pathways involved in apoptosis, necroptosis and cell survival following death receptor activation, and highlights the influence of the molecular switch, cFLIP, on cell fate.